Skip to main content
OpenTrials
Completed

NCT Number: NCT00419952

A Comparison of SYMBICORT® pMDI With Budesonide HFA pMDI in African American Subjects With Asthma.

The purpose of this study is to determine the effectiveness and safety of SYMBICORT® pMDI (a medication approved by the Food and Drug Administration, FDA) in the African American population.

Completed

Looking for future studies?

Notify Me

Key information

Age range

12 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Research Site, Birmingham, Alabama, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or Female, African American (self-reported), ≥12 years of age
  • Moderate to severe asthma requiring treatment with an inhaled corticosteroid
  • Diagnosis of asthma for at least 6 months

Exclusion criteria

  • Subjects requiring treatment with systemic corticosteroids (e.g., oral, parenteral, ocular)
  • Any significant disease or disorder that may jeopardize a subject's safety

Treatment and study plan

Budesonide/formoterol (SYMBICORT) pMDI

Drug

Symbicort pMDI 160/4.5 ug x 2 actuations twice daily (BID)

Budesonide HFA pMDI

Drug

Budesonide HFA pMDI 160 ug x 2 actuations BID

Primary outcomes

  1. Total Number of Asthma Exacerbations

    Time frame: 52 Weeks

    An exacerbation was defined as symptomatic worsening requiring oral/systemic glucocorticoid therapy and/or emergency room visit and/or urgent care center visit and/or hospitalization.

Secondary outcomes

  1. Asthma Exacerbations

    Time frame: 52 Weeks

    Number of participants with at least 1 exacerbation

  2. QT Interval Corrected Using the Fridericia Formula Measured Via Electrocardiogram (ECG)

    Time frame: Baseline and 52 weeks

    QT interval corrected using the Fridericia formula [QTc (Frid)] - Change from baseline to end of treatment

  3. Number of Patients With Shift From Normal to High Rate of Total Ectopic Ventricular Beats as Measured by 24-hour Holter Monitor Assessment

    Time frame: Baseline and 2 weeks (visit 4)

    Total ectopic ventricular (VE) beats - number of participants with shift from normal (<50) to high (≥50) from baseline to visit 4.

  4. Number of Patients With Shift From Normal to High Rate of Total Ectopic Supraventricular Beats as Measured by 24-hour Holter Monitor Assessment

    Time frame: Baseline and 2 weeks (visit 4)

    Total ectopic supraventricular (VE) beats - number of participants with shift normal (<50) to high (≥50) from baseline to visit 4.

  5. Total Number of Ventricular Runs as Measured by 24-hour Holter Monitor Assessment

    Time frame: Baseline and 2 weeks (visit 4)

    Total ventricular runs - number of participants with shift normal (<1) to high (≥1) from baseline to week 2.

  6. Diary Assessments - Rescue-free Day

    Time frame: baseline and 52 weeks

    Calculated as the number of rescue-free days divided by the number of non missing days in the baseline period times 100%. The results are expressed as the change in % rescue-free days in the baseline period and the active treatment period. A rescue-free day was one in which the patient answered "no" to having used rescue medication that day

  7. Diary Assessments - Symptom-free Day

    Time frame: baseline and 52 weeks

    Calculated as the number of symptom-free days divided by the number of non missing days in the baseline period times 100%. The results are expressed as the change in % symptom-free days in the baseline period and the active treatment period. A symptom-free day was one in which the patient answered "no" to having symptoms that day

  8. Diary Assessments - Asthma-control Day

    Time frame: baseline and 52 weeks

    Calculated as the number of asthma control days divided by the number of non missing days in the baseline period times 100%. The results are expressed as the change in % asthma control days in the baseline period and the active treatment period. An asthma control day was one in which the patient answered "no" to having symptoms and "0" to the use of rescue medication that day

  9. Onset of Effect Questionnaire (OEQ)

    Time frame: 1 week

    Number of participants with positive response to Item 2 in questionnaire "During the past week,you could feel your study medication begin to work right away. A positive response was defined as a response of "strongly agree" or "somewhat agree"

  10. Onset of Effect Questionnaire (OEQ)

    Time frame: 1 week

    Number of participants with positive response to Item 5 in questionnaire "During the past week, you were satisfied with how quickly you felt your study medication begin to work." The scale was scored on a 5-point Likert scale from strongly agree to strongly disagree. A positive response was defined as a response of "strongly agree" or "somewhat agree"

  11. Peak Expiratory Flow (PEF) in Morning

    Time frame: baseline and 52 weeks

    Change in AM PEF from baseline (mean over the 2 weeks run-in) to the average of the randomized treatment period.

  12. Forced Expiratory Volume in One Second (FEV1)

    Time frame: baseline and 52 weeks

    Change in pre-dose FEV1 from baseline (end of run-in, visit 3) to the average of the randomized treatment period

  13. Asthma Treatment Satisfaction Measure (ATSM)

    Time frame: Baseline and 52 weeks

    Overall score - change from baseline to end of treatment. For 11 individual attributes, expectations were subtracted from the outcomes. This difference and the importance rating were combined in a weighted average which was then multiplied by the raw satisfaction measure. The final derived satisfaction measure was transformed to a 0 to 100 scale, with higher scores representing greater satisfaction.

Sponsors and collaborators

Lead sponsor

AstraZeneca

Industry

Registry information

Official study title

A 52-week, Randomised, Double-blind, Parallel-group, Multi-centre, Phase IIIB Study Comparing the Long Term Safety of SYMBICORT® pMDI 160/4.5 mg x 2 Actuations Twice Daily to Budesonide HFA pMDI 160 mg x 2 Actuations Twice Daily in Adult/Adolescent (≥12 Years) African American Subjects With Asthma

Important dates

Study start
2007
Primary completion
2009
Study completion
2009
First posted
Jan 9, 2007
Registry last updated
Oct 30, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.